pocketful logo
Bliss GVS Pharma Ltd logo

Bliss GVS Pharma Ltd

NSE: BLISSGVS BSE: 506197

₹276.76

(3.52%)

Sat, 09 May 2026, 00:00 am

mtf coin illustrationMTF 5x

Bliss GVS Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    2849.43

  • Net Profit

    90.26

  • P/B

    1.18

  • Sector P/E

    34.14

  • P/E

    14.69

  • EV/EBITDA

    6.82

  • Debt/Equity (Industry)

    0.27

  • Interest Cover (Industry)

    10.76

  • ROCE (Industry)

    16.38

  • RONW (Industry)

    14.42

  • ROE

    8.95

  • ROCE

    12.09

  • Debt/Equity

    0.09

  • EPS (TTM)

    10.46

  • Dividend Yield

    0.18

  • Book Value

    107.04

  • Interest Cover

    16.47

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (10.3x coverage).
  • Bliss GVS Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Bliss GVS Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bliss GVS Pharma is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Bliss GVS Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • High level of physical assets or inventory.
  • Shibroor's remuneration is higher than average for companies of similar size in India.
  • Bliss GVS Pharma is not covered by any analysts.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters35.3635.3635.3935.4435.29
FII10.4514.5413.2712.6513.18
DII5.045.785.986.546.55
Public49.1544.3245.3645.3644.98
Government00000

Read More

Technical Analysis

RSI

59.85

MACD

10.63

50 DMA

236.50

200 DMA

182.71

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic380.75320.05298.41259.35237.71198.65137.95
Fibonacci320.05296.87282.54259.35236.17221.84198.65
Camarilla293.45287.89282.32259.35271.20265.63260.07

Pivots Level: Classic

R3

+121.40

380.75

R2

+60.70

320.05

R1

+39.05

298.41

259.35
259.35
Pivot Point
LTP: 269.65

S1

-21.65

237.71

S2

-60.70

198.65

S3

-121.40

137.95

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    268.91

  • 20-EMA

    261.88

  • 30-EMA

    254.08

  • 50-EMA

    240.46

  • 100-EMA

    217.00

  • 200-EMA

    192.16

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
10 Feb 2026dividend₹0.50 Dividend /Share18 Feb 2026
10 Feb 2026board-meetingsQuarterly Results, Interim Dividend
18 Jan 2026dividendInterim Dividend - Re 0.50 Per Share18 Feb 2026
06 Nov 2025board-meetingsQuarterly Results
24 Jun 2025dividendFinal Dividend - Rs. - 0.524 Jul 2025
12 May 2025dividend₹0.50 Dividend /Share24 Jul 2025
12 May 2025agm
18 Jun 2024dividendAnnual General Meeting/Dividend - Rs 0.50 Per Share19 Jul 2024
02 May 2024dividend₹0.50 Dividend /Share19 Jul 2024
02 May 2024agm

Read More

Peer Comparison

Bliss GVS Pharma Ltd logo

Bliss GVS Pharma Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Bliss GVS Pharma Ltd About

Bliss GVS Pharma is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company is one of among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1984

Headquarters

CEO

Nandkumar Kashinath Chodankar

Employees

Contact

Website icon

Website

http://www.blissgvs.com

Email icon

Email

cs@blissgvs.com; info@blissgvs.com

Phone icon

Phone

91-22-42160000

Location icon

Location

102 Hyde Park Sakivihar Road, Andheri East, Mumbai, Maharashtra, 400072

Read More

Bliss GVS Pharma Ltd Company History

YearHistory
2012
  • Company has acquired 70% management stake in the Company M/s. Kremoint Pharma Private Limited
2013
  • Bliss GVS Pharma Ltd recommended a dividend of 40%
  • Bliss GVS receives recognition for its Research & Development Lab from the Department of Scientific & Industrial Research (DSIR), Government of India.
2014
  • Bliss GVS is named in Moneylife magazine's 'Wealth Creators 2004-2013' list
  • Bliss GVS Wins - Outstanding Exports Award.
2015
  • Bliss GVS Pharma wins Healthcare Services contract in Kenya
2016
  • Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
HRTI PRIVATE LIMITEDSell581292224.8625 Mar 2026
HRTI PRIVATE LIMITEDBuy517506224.2625 Mar 2026
RATNABALI EQUITY PRIVATE LIMITEDSell717102212.1120 Mar 2026
RATNABALI EQUITY PRIVATE LIMITEDBuy717000212.5620 Mar 2026
ARIAN INVESTMENT LTDSell1000000210.8219 Mar 2026
MATEUS LTDBuy933978210.8119 Mar 2026
MANSUKH SECURITIES & FINANCE LIMITEDBuy620900220.8124 Feb 2026
MANSUKH SECURITIES & FINANCE LIMITEDSell620900216.2224 Feb 2026
HRTI PRIVATE LIMITEDBuy959323232.8717 Feb 2026
QE SECURITIES LLPBuy583870234.2817 Feb 2026

Read More

Bliss GVS Pharma Ltd News

Bliss GVS Pharma Board Meet Set for May 12, 2026

Bliss GVS Pharma schedules board meeting on May 12, 2026, to approve Q4 FY26 audited financial results and consider final dividend for FY26.

05 May 2026

companies

Bliss GVS Pharma Announces Postal Ballot for Director Appointments

Bliss GVS Pharma Limited has issued a postal ballot notice for the appointment of two independent directors through remote e-voting from April 10 to May 9, 2026.

10 Apr 2026

companies

Bliss GVS Pharma Issues Postal Ballot Notice

Bliss GVS Pharma Limited issued postal ballot notice for shareholder approval of two independent director appointments with voting period from April 10-May 09, 2026.

09 Apr 2026

companies

Bliss GVS Pharma Gets ICRA Credit Rating Assignment

Bliss GVS Pharma Limited receives [ICRA]A-(Stable)/[ICRA]A2+ rating for Rs. 100.00 crore fund-based and non-fund-based facilities from ICRA Limited on April 08, 2026.

08 Apr 2026

companies

Bliss GVS Pharma Extends Share Transfer Window

Bliss GVS Pharma Limited announces extension of special window for re-lodgement of physical share transfer requests until February 04, 2027, following SEBI circular dated January 30, 2026.

06 Apr 2026

companies

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800